CD6 as a Cell Surface Receptor and As a Target for Regulating Immune Responses

Author(s): Marion H. Brown.

Journal Name: Current Drug Targets

Volume 17 , Issue 6 , 2016

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

CD6 has been exploited as a drug target as its expression is restricted, primarily to T cells, it has a well characterised cell surface ligand, CD166 and regulates T cell activation through a long cytoplasmic tail. CD6 can affect both the initiation and maintenance of T cell function in a negative and positive manner respectively so that it is important to understand these dual effects of a potential drug target. The effective mode of action of clinical monoclonal antibodies (mAbs) that recognise cell surface receptors including CD6 is commonly cytotoxic depletion of cells. It is not clear how current therapeutic strategies to target CD6 perturb function. With the benefit of new structural data, this review provides a critical analysis and interpretation of experiments in which various reagents have been tested and offers some suggestions as how more effective drugs may be developed.

Keywords: CD6, CD166, SLP-76, T cells, activation, inhibition, immunotherapy, signal transduction.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 17
ISSUE: 6
Year: 2016
Page: [619 - 629]
Pages: 11
DOI: 10.2174/1389450116666150825120536
Price: $58

Article Metrics

PDF: 50
HTML: 6
EPUB: 1